

Dissemination, implementation & monitoring of National Institute for Health and Care Excellence (NICE) Guidance, and other Nationally Agreed Best Practice

This Policy describes the process for the dissemination, implementation, & monitoring, of National Institute for Health and Care Excellence (NICE) Guidance, and other Nationally Agreed Best Practice

Key Words:	NICE, Guidance, Agreed Best Practice	
Version:	8	
Adopted by:	Trust Policy Committee	
Date this version was adopted:	30 November 2020	
Name of Author:	Associate Director for Quality Improvement/NICE & Effectiveness Officer	
Name of responsible Committee:	Clinical audit NICE and QI Committee	
Please state if there is a reason for not publishing on website:	n/a	
Date issued for publication:	November 2020	
Review date:	November 2021	
Expiry date:	1 June 2022	
Target audience:	All LPT staff	
Type of Policy	Clinical ✓	Non Clinical ✓
Which Relevant CQC Fundamental Standards?	R9, R12,R14, R15, R17 & R18	

Contents

Version Control	3
Equality Statement	4
Due Regard	4
Definitions that apply to this policy	4
1.0 Purpose of the Policy	6
2.0 Summary of the Policy	6
3.0 Introduction	6
4.0 Scope of the policy	6
5.0 Duties within the Organisation	8
6.0 Process for identifying and dissemination of relevant documents	11
7.0 Process for conducting an organisational gap analysis	12
8.0 Process for ensuring that recommendations are acted upon throughout the organisation	13
9.0 Process for documenting any decision not to implement NICE recommendations	13
10.0 Training needs	13
11.0 Monitoring compliance and effectiveness	14
12.0 Standards/performance indicators	17
13.0 References and bibliography	17
14.0 Associated documentation	17
Appendix 1 – Financial decisions in relation to cost implications	18
Appendix 2 – NICE guidance, relevance, compliance, dissemination and clinical audits	19
Appendix 3 – Exceptions, assurance and reporting to Divisional Clinical Audit and Effectiveness Group, Quality Assurance Committee and commissioners	20
Appendix 4 – NHS constitution document	21
Appendix 5 – Stakeholders and consultation	22
Appendix 6 – Due regard screening template	23
Appendix 7 – Privacy impact assessment screening	24

Version Control and Summary of Changes

History of former organisations' policies		
LPT		November 2010 (no policy ref. number)
LCRCHS	Version 2	November 2009 CHSQCD002
LCCHS	Version 1	February 2010 LCCHSCP182
Version number	Date	Comments (description change and amendments)
Version 1.0	Dec 2011	Harmonisation of former organisations' policies
Version 2.0	Feb 2012	Comments incorporated received from key staff.
Version 2.1	8 Feb 2012	Policy approved at the Senior Clinical Quality Group subject to minor amendments.
Version 2.2	14 Feb 2012	Gone to Quality Assurance Committee for ratification.
Version 3.0	May 2013	Revised policy
Version 3.1	15 Aug 2013	Policy approved at Policy Group meeting subject to minor amendment in readiness to be adopted at the next QAC meeting.
Version 4.0	17 Jun 2016	Elena Relph & Julie Warner – Grammatical and reference amendments. Fern Barrell – Risk register and CEG involvement clarification. Jude Smith - Confirmation of Clinical Directors' financial involvement. 360 Assurance – approval of BAT when compliant (see 6.7 point 2)
Version 5.0	1 Aug 2016	Circulation list updated and sent to additional Clinical Directors (no additional comments received by deadline of 19 August 2016).
Version 6.0	Dec 2016	Reference to NHS Litigation Authority (NHSLA) removed from section 13 and appendix 4.
Version 7.0	Jun 2018	Amendments made due to movement of responsibility from CQETL to HOP.
Version 8.0	Sept 2020	Amendments made due to appointment of Associate Director for Quality Improvement and as a result of actions required in 360 Assurance Clinical Audit and NICE report.

For further information contact:

Improvement Knowledge Hub core team at WelImproveQ@leicspart.nhs.uk.

Equality Statement

Leicestershire Partnership NHS Trust (LPT) aims to design and implement policy documents that meet the diverse needs of our service, population and workforce, ensuring that none are placed at a disadvantage over others. It takes into account the provisions of the Equality Act 2010 and promotes equal opportunities for all. This document has been assessed to ensure that no one receives less favourable treatment on the protected characteristics of their age, disability, sex (gender), gender reassignment, sexual orientation, marriage and civil partnership, race, religion or belief, pregnancy and maternity.

Due Regard

LPT will ensure that Due regard for equality is taken and as such will undertake an analysis of equality (assessment of impact) on existing and new policies in line with the Equality Act 2010. This process will help to ensure that:

- Strategies, policies and services are free from discrimination;
- LPT complies with current equality legislation;
- Due regard is given to equality in decision making and subsequent processes;
- Opportunities for promoting equality are identified.

Please refer to due regard assessment (Appendix 6) of this policy.

Definitions that apply to this Policy

Best practice guidance	This policy refers to clinical guidance documents and any high level enquiry documents that make recommendations for patient safety.
Nationally agreed	Documents that have been published by national organisations which have an official advisory or regulatory role for the National Health Service.
NICE	The National Institute for Health and Care Excellence (NICE) is the independent organisation responsible for providing national guidance on treatments and care for people using the NHS in England and Wales.
CG	NICE Clinical Guideline - guidance on the appropriate treatment and care of people with specific diseases and conditions.
NG	NICE Guideline – Replaced CG in January 2015 as a means to identify new clinical guidance.
IPG	NICE Interventional Procedures Guidance - on procedures used for diagnosis or treatment that involves incision, puncture, entry into a body cavity, electromagnetic or acoustic energy.
TAG	NICE Technology Appraisal –Guidance on the use of new and existing medicines and treatments.
PH	NICE Public Health guidance provides guidance on the promotion of good health and the prevention of ill health. These are: “Public Health Intervention Guidance” and “Public Health Programme Guidance”
QS	NICE Quality Standards - A concise set of statements designed to drive and measure high-priority quality improvements in a particular area of care and to achieve improved quality of care in local settings.

	General Public and People receiving health care services, can access information about the quality of services and care they should expect from their health care provider
DAP	NICE Diagnostics Assessment Programme - (DAP) focuses on the evaluation of innovative medical diagnostic technologies in order to ensure that the NHS is able to adopt clinically and cost effective technologies rapidly and consistently.
MTG	NICE Medical Technologies Guidance - considers a single medical device or diagnostic technology which provides equivalent or enhanced clinical outcomes for equivalent or reduced cost.
NCE	National Confidential Enquiry (NCE) -There are three independent enquiries: the Centre of Maternal and Child Enquiries (CMACE), the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) and the National Confidential Inquiry into Suicide and Homicide by People with Mental Illness (NCISH). All three investigate the contribution of deficiencies in care that led to serious adverse patient outcomes and identify areas where clinical practice needs to be improved and make appropriate recommendations.

1.0. Purpose of the Policy

It is necessary to have a consistent approach and a clearly identified process for the evaluation, dissemination, implementation and monitoring of NICE and other good practice guidance across LPT.

The purpose of this policy is to ensure the appropriate implementation of NICE and other good practice guidance, in line with guidance published by NICE, Practical steps to improving the quality of care and services using NICE guidance (2018) and Principles for putting evidence-based guidance into practice (2018) and to comply with requirements as set out by the Care Quality Commission (CQC) Regulations 9 and 12.

2.0. Summary and Key Points

This policy outlines the system and processes for the dissemination, implementation and monitoring of NICE and other good practice guidance throughout LPT. National “best practice” guidance enables staff to make evidence based decisions about treatment and healthcare.

3.0. Introduction

In the white paper “*First Class Service: Quality in the NHS*”, the Department of Health declared that all patients should have fair access to high quality care which is based on clear evidence of best practice (DH 1999). From this white paper came the implementation of the National Institute for Health and Care Excellence (NICE) and the National Service Frameworks (NSFs). As a result of the findings of the Francis report 2013, The Department of Health produced *Hard Truths: The journey to putting patients first* 2014. Reports by Keogh 2013 - ‘Review into the quality of care and treatment provided by 14 hospital trusts in England: overview report’ and Berwick 2013 ‘Improving the Safety of Patients in England’ highlighted failings in patient care and their safety’ which provided the basis for further patient centred care guidance.

4.0 Scope of the policy

This policy covers the implementation and monitoring of all national guidance for best practice within LPT. It sets out a coordinated process to identify and disseminate relevant documents. In addition it covers conducting an organisational gap analysis and monitoring of the implementation process.

For the purposes of this document, the term, “guidance” is a collective term, and applies to guidance from a range of nationally recognised sources:

This Policy applies to all staff within LPT involved in any aspect of the review and/or recommendations from nationally agreed best practice guidance documents.

4.1 National Institute for Health and Care Excellence - (Technology Appraisals, NICE Guidelines and Quality Standards).

NICE guidance is:

- Intended to improve the outcomes for people who access health service providers.
- Produced by health and social care professionals, patients and the public.
- Evidence based guidance and advice for health, public health and social care practitioners.
- Transparent in its development, consistent, reliable and based on a

- rigorous development process.
- Evaluated, weighing up the cost and benefits of treatments to ensure money is well spent.
- Internationally recognised for its excellence.
- Issued as NICE (formerly clinical) guidelines, interventional procedures guidance, public health guidance, medical technologies guidance, diagnostic guidance and technology appraisals.

NICE also produce Pathways that provide guidance on the range of guidance available for a range of topics.

4.2 NICE Guidelines

- Are recommendations by NICE on the appropriate treatment and care of people with specific diseases and conditions within the NHS.
- Based on the best available evidence.
- Assist health professionals in their work but do not replace their knowledge.

4.3 Technology Appraisals

- Are guidance on the use of new and existing medicines and treatments.
- Assess the clinical and cost effectiveness of health technologies.
- Have stated timescales associated with them and must be implemented within three months of their publication.

4.4 NICE Quality Standards

- Are a concise set of statements designed to drive and measure priority quality improvements within a particular area of care.
- Are derived from the best available evidence such as NICE guidance and other evidence sources accredited by NICE.
- Enable service providers to quickly and easily examine the performance of their organisation and assess improvement in standards of care they provide.
- Provide the general public and people receiving health care services with easily accessible information about the quality of services and care they should expect from their healthcare provider.

4.5 Public Health Guidance

- Makes recommendations for populations and individuals on activities, policies and strategies that can help prevent disease or improve health.
- May focus on a particular topic, a particular population or a particular setting.

4.6 National Confidential Enquiries (NCEs) – NCEPOD, CMACE & NCISH

Following national enquiries, changes in practice are often recommended, e.g. The Laming Report following the Climbié Investigation.

There are three National Confidential Enquiries: the Centre of Maternal and Child Enquiries (CMACE), the National Confidential Enquiry into Patient Outcome and Death (NCEPOD) and the National Confidential Inquiry into Suicide and Homicide by People with Mental Illness (NCISH).

All three investigate deficiencies in care that have led to serious adverse

patient outcomes and identify areas where clinical practice requires improvement and make appropriate recommendations.

4.7 Care Quality Commission (CQC)

The Care Quality Commission undertakes special reviews and studies, which look in-depth at different aspects of health and adult social care, to assess and drive improvement for people using the services e.g. how well the health and social care pathway is working for people who had a stroke and their carers.

5.0 Duties within the Organisation

It is recognised that adequate implementation of National Guidance requires a robust process that involves all LPT staff.

5.1 The Chief Executive

- Is accountable for the implementation of this policy and ensuring that LPT has a process for the consideration, dissemination and implementation of all National Guidance.

5.2 LPT Trust Board

- Will ensure that LPT operates effectively and efficiently and fulfils all its statutory duties and responsibilities in accordance with the approved LPT Scheme of Delegation, including delegation to the Clinical Effectiveness Group.

5.3 Medical Director

- Will appoint a Trust lead to receive and co-ordinate response to information requests for the National Confidential Inquiry for Suicides and Homicides and any other enquiries as needed.
- Work with the Clinical Directors to estimate the cost of additional resources for the implementation of non-drug specific NICE guidance and support the negotiation of resources. (Appendix 1)
- Also work with the Clinical Directors to ensure the operational delivery of all National Guidance.

5.4 The Head of Pharmacy (HoP)

- Will work with the NICE and Effectiveness Officer (NEO) and Directorate Governance leads to agree which guidance is relevant to the Trust and to provide a rationale for those guidance which are clearly not relevant to LPT.
- Receive medicines related NICE guidance from the NEO and establish relevance for each Directorate.
- Contribute to the completion of baseline assessment tool (BAT) as required.
- Work in collaboration with the Medical Director and Clinical Directors to assess financial implications (Appendix 1).

5.5 Clinical Directors

- Will advise service leads/service managers in an assessment of the financial/contractual implications associated with implementation of NICE guidance (Appendix 1).
- Will assess, in conjunction with the relevant approving group, the evidence provided to support the completion of NICE guidance

documentation in order to establish completeness and compliance.

5.6 Directorate Clinical Governance Leads

Each Directorate Clinical Governance Lead (or appropriate clinical lead) will work with the NEO to:

- Confirm relevance/non-relevance of NICE guidance and Technology Appraisals within 2 weeks.
- Identify individual(s) to complete the baseline assessment tool (BAT), if guidance deemed to be relevant to their service area and when full compliance has been confirmed ensure that it is approved.
- Disseminate guidance to appropriate services throughout the directorate.
- Respond to exceptions highlighted by the NEO regarding confirmation of relevance, evidence of dissemination and completion of the BAT.
- Ensure NICE and National Guidance is a standing agenda item for the 'relevant divisional sub group' of Clinical Governance Group.
- Identify risk associated with the implementation of guidance and update risk register as appropriate.
- Oversee implementation of action plan within BAT.
- Identify NICE related clinical audits in partnership with NEO and consider whether Clinical Audit is the appropriate means of confirming compliance with NICE guidance or if there are other means of assurance.
- Ensure compliance with Technology Appraisals is confirmed within 3 months of publication.
- Ensure that confirmation of compliance with other NICE guidance is completed within an appropriate timescale.

5.7 Quality Assurance Committee (QAC)

- Will assess assurances received from the CEG related to the implementation of Guidance.
- Ratify decisions not to implement Guidance.

5.8 Clinical Effectiveness Group (CEG)

- Will receive assurance reports from the Associate Director for Quality Improvement/NEO.
- If required, identify a senior lead to implement cross-divisional work (E.g. development of trust-wide pathway, training plan or clinical audit)
- Approve decisions not to implement Guidance and report their decisions to QAC.
- Ensure that identified risks related to non-compliance are escalated to QAC and recorded on the risk register.
- Agree and monitor priority NICE clinical audits.

5.9 Clinical Audit, NICE and Quality Improvement Committee (CANQI Committee)

The CANQI Committee has oversight of the progress of NICE implementation work within the Trust. It will receive reports from the NEO giving a review of the number of outstanding actions and action plans in place to address non-

compliant recommendations, the number and stage (not started, incomplete, complete) of NICE baseline assessment tool completion, details of guidance that has been escalated due to lack of progress and guidance that has been closed as fully compliant or partially compliant. It will also monitor completion of NICE BATs within the 18 month timeframe following publication.

5.10) Associate Director for Quality Improvement

- Oversee NICE reporting and assurance mechanisms.
- Work with Directorate Clinical Governance Leads to escalate exceptions.
- Ensure links between NICE and clinical audit are integrated and supported by the clinical audit forward plan.

5.11 NICE and Effectiveness Officer (NEO)

- Oversee and co-ordinate the Trust NICE guidance implementation procedure.
- Identify new NICE guidance published on the NICE website on a monthly basis.
- Work with the Associate Director for Quality Improvement, Directorate Governance Leads and Head of Pharmacy to agree which guidance is relevant to the Trust and to provide a rationale for guidance which are not relevant to LPT.
- To receive a response from the Directorate Clinical Governance Leads on the relevant/non-relevant guidance within two weeks.
- Receive names of individual(s) to review NICE guidance from Directorate Clinical Governance Leads (DCGLs).
- To send the relevant BAT to the nominated individual(s) to complete providing support if necessary.
- Collate completed BATs and Quality Standard compliance templates from each Directorate.
- Collate evidence of dissemination of guidance from each Directorate.
- Inform Directorate Clinical Governance Leads of areas which require action plans, cross-referencing with other divisions to avoid duplication of effort.
- Collate evidence of implementation updating the NICE database with details of progress towards implementation, identifying high priority and significant recommendations and acting accordingly.
- Support Directorates to identify and deliver NICE related clinical audits.
- Provide status reports to each Directorate Clinical Audit and Effectiveness Group (sub groups of Directorate Clinical Governance Groups). To include clinical audit, cost implications and exceptions at each stage, e.g. confirmation of relevance, completion of BATs, evidence of dissemination and implementation.
- Where the baseline assessment reveals a need for additional financial investment/resource ensure the procedure in Appendix 1 is followed.
- Provide assurance reports for the Commissioners in line with the Quality Schedule.
- To be aware of areas of risk which potentially are to be re-assessed e.g. where NICE guidance has been revised, new services or areas of organisational risk/Serious Incidents, via the Head of Pharmacy, Associate Director for Quality Improvement and the Clinical Effectiveness Group (CEG).
- Provide assurance reports for all guidance for the CEG.

- Maintain a comprehensive database of all stages of the implementation procedure and related correspondence, including rationale for non-relevant guidance.

5.12 Responsibility of Clinical Staff

- All staff have a professional responsibility to implement relevant guidance and make evidence based decisions about treatment and health care.
- Clinical staff must ensure that the patients' electronic record is checked regarding consent and that consent has been sought and obtained before any care, intervention or treatment described in this policy is delivered. Consent can be given orally and/or in writing. Someone could also give non-verbal consent as long as they understand the treatment or care about to take place. Consent must be voluntary and informed and the person consenting must have the capacity to make the decision. Clinical staff must then record the information relating to patients' consent on the electronic patient record.
- In the event that the patient's capacity to consent is in doubt, clinical staff must ensure that a mental capacity assessment is completed and recorded. Someone with an impairment of or a disturbance in the functioning of the mind or brain is thought to lack the mental capacity to give informed consent if they cannot do one of the following:
 - Understand information about the decision.
 - Remember that information.
 - Use the information to make the decision.
 - Communicate the decision.

6.0 Process for Identifying and Dissemination of Relevant Documents

6.1 NICE guidance

An up-to-date schedule of forthcoming NICE guidance is available on the NICE website (www.nice.org.uk).

All guidance issued by NICE each month will be reviewed initially by the NEO and confirmed by the Head of Pharmacy in terms of potential relevance to LPT. The NEO will then disseminate details of all NICE guidance to the Directorate Clinical Governance Leads. If guidance is considered relevant to their areas, the Clinical Governance Leads will nominate individual(s) accordingly. The NEO will forward the NICE baseline assessment tool (BAT) and NICE guidance to the nominated individuals for completion and return, confirming full compliance or detailing any action required/risks identified. The nominated lead will supply the NEO with electronic copies of documents used as evidence of compliance, e.g. Standard Operating Guide, patient leaflet, link to Trust policy (where a Trust policy is used as evidence in the BAT, the nominated lead will state which section of the policy covers the recommendation). The nominated lead will also work with the NEO to establish an action plan for any non-compliant recommendations (using SMART guidelines), monitor the actions and update the NEO with progress.

A BAT is published by NICE for the majority of all new NICE guidance. This incorporates all required recommendations, a baseline assessment of compliance, and an action plan.

The BAT enables detailed consideration of the guidance and provides the Trust with a process for conducting an organisational gap analysis.

The NEO, Head of Pharmacy, Associate Director for Quality Improvement and Directorate Clinical Governance Leads then monitor baseline assessment tools, in terms of delivery and follow up. It is expected that the initial review of the BAT will be completed within 3 months of publication and the final position of compliance to be completed with 18 months of publication.

Appendix 2 outlines the process and responsibilities for reviewing relevance, compliance and dissemination of NICE guidance.

6.2 Clinical Audit and other Quality Improvement methodologies

The National Institute for Health and Care Excellence, Principles for Best Practice in Clinical Audit (NICE: 2010) state that:

“Clinical audit is a quality improvement process that seeks to improve patient care and outcomes through systematic review of care against explicit criteria and the implementation of change.”

Through clinical audit, services can measure compliance against the recommendations made by the NICE guidance and improve patient care.

The Directorate Governance Leads and the NEO consider relevant NICE guidance for inclusion in the Clinical Audit Forward Plan. NICE produces clinical audit tools and Quality Standards to inform clinical audits.

Where other methodologies are more appropriate, e.g. quality improvement or service evaluation, appropriate action will be taken and assistance provided where necessary, see Appendix 2.

The Clinical Audit policy defines four categories of Clinical Audit. All NICE related audits are ‘Priority level 2’, which are ‘Internal must do audits’.

6.3 National Service Framework, National Confidential Enquiries and other High level Enquiries including Care Quality Commission Service Reviews

At the weekly Executive Team meeting all non-NICE national publications relevant to LPT will be considered and leads will be identified for further action as required. In addition other relevant publications can be received by the NEO via other routes such as: CEG and from Clinical Leads.

The NEO will log the names of the leads for each publication and record evidence of a gap analysis and outcomes.

7.0 Process for conducting an Organisational Gap Analysis

Implementation of all types of guidance will have an impact on the provision of services and require a system for assessing the gaps and action planning. For NICE guidance the BAT is used.

For other guidance the NEO will contact the lead identified at the Executive Team meeting or CEG and establish:

- Standard requirement
- Current situation
- What's missing
- What needs to be done
- Priority
- Responsibility
- Time scales

(Gap analysis is based on the Lloyds Register LRQA ISO 9001 model).

7.1 Resource and financial implications

It is recognised that implementation of guidance will often have a financial impact.

The process to be followed in relation to financial decisions and cost implications is outlined in Appendix 1. Resource implications will be detailed in a NICE cost assessment template. Copies of this and other correspondence will be kept on the Trust NICE database maintained by the NEO.

7.2 Financial Planning

Where Directorates have identified cost implications associated with the implementation of guidance, recommendations will be built into contractual discussions on an annual basis lead by the Director of Finance, Business & Estates. (Appendix 1)

8.0 Process for ensuring that recommendations are acted upon throughout the organisation

Regular reports from Associate Director for Quality Improvement/NICE & Effectiveness Officer outlining performance and exceptions in terms of dissemination, action planning, implementation, or clinical audit, will be reported to:

- Directorate Clinical Governance Leads/Directorate Clinical Audit and Effectiveness Group/divisional sub-groups (Appendix 3)
- Clinical Audit, NICE and Quality Improvement Committee (CANQI) (Appendix 3)
- CEG (Appendix 3)
- Quality Assurance Committee (Appendix 3)
- Commissioners (Appendix 3)

9.0 Process for documenting any decision not to implement NICE recommendations

Any decision not to implement National Guidance must be approved by the Clinical Effectiveness Group and ratified by the Quality Assurance Committee.

10.0. Training needs

There is no training requirement identified within this policy.

11.0. Monitoring Compliance and Effectiveness

The Associate Director for Quality Improvement will audit this document by means of a review of the records maintained by the NEO on an annual basis against the following standards:

- National guidance is disseminated according to this policy
- A gap analysis is undertaken against all new guidance
- Recommendations are acted upon
- A report providing commissioner assurance

Duties outlined in this Policy will be evidenced through monitoring of the other minimum requirements. Where monitoring identifies any shortfall in compliance the Clinical Effectiveness Group (CEG) shall be responsible for developing and monitoring any action plans to ensure future compliance.

Minimum Requirements	Evidence for Self-assessment	Process for Monitoring	Responsible Individual/Group	Frequency of monitoring
How the organisation identifies which NICE guidelines are relevant to its services	Divisional Clinical Governance Lead	The NICE guidance is reviewed on a monthly basis by the Head of Pharmacy and NEO who identify guidelines relevant to services within the directorates. This is then validated by the directorate clinical governance leads.	Head of Pharmacy	On a monthly basis
How a gap analysis is conducted to identify shortfalls	National Service Framework, National Confidential Enquiries and other High level Enquiries including Care Quality Commission Service	Divisional Clinical Governance Leads identify gaps CEG escalate gaps to QAC	NEO records gap analysis	Quarterly NICE position report to CEG and additional exception reports as

Minimum Requirements	Evidence for Self-assessment	Process for Monitoring	Responsible Individual/Group	Frequency of monitoring
	Reviews			required. Bi-monthly reports to directorates and CANQI.
How action plans are created to address any shortfalls, including recording decisions not to implement NICE guidelines	Process for conducting an Organisational Gap Analysis	Plans to address shortfalls are developed by the divisional clinical governance leads or Trust- wide via CEG. Decision not to implement are made by QAC	Divisional Clinical Governance Leads Medical Director, Chair of Senior Clinical Quality Group and QAC	As above
How the organisation responds to requests for data	National Service Framework, National Confidential Enquiries and other High level Enquiries including Care Quality Commission Service Reviews	All non-NICE national publications relevant to LPT considered and leads will be identified for further action as required and logged on the forward plan and non-NICE related publication database.	Executive Team will consider all non-national publications at the weekly Executive team meeting and identify leads to complete the gap analysis and provide data.	Weekly
How the organisation identifies which National Confidential Enquiry/Inquiry recommendations are relevant to its services	National Confidential Enquiries (NCEs) – NCEPOD, CEMACH, NCISH (page 9)	As above	As above	As above

Minimum Requirements	Evidence for Self-assessment	Process for Monitoring	Responsible Individual/Group	Frequency of monitoring
How a gap analysis is conducted to identify shortfalls	National Service Framework, National Confidential Enquiries and other High level Enquiries including Care Quality Commission Service Reviews	NEO would contact the lead identified at the Executive team meeting or SCQG to carry out section 7.0 within the NICE policy	CEG Executive Team Divisional Clinical Governance Leads	Quarterly
How action plans are developed to address any shortfalls, including recording decisions not to implement National Confidential Enquiry/Inquiry recommendations	Process for conducting an Organisational Gap Analysis	Monitoring via the Executive Team. Shortfall Reports from Associate Director for Quality Improvement /NEO/ Quality & Data Analyst outlining performance and exceptions in terms of action planning and implementation or clinical audit	Divisional Clinical Governance Leads CEG and additional exception reports as required. Escalate gaps to QAC.	Annually

12.0. Link to standards

This policy links to Care Quality Commission (CQC) standards:

- 9. Person centred care
- 12. Safe care and treatment
- 14. Meeting nutritional and hydration need
- 15. Premises and Equipment
- 17. Good governance
- 18. Staffing

13.0. References and Bibliography

The policy was drafted with reference to the following:

[Chief Medical Officer Annual Report: Learning how to learn: Compliant with Patient Safety Alerts in the NHS \(2005\)](https://webarchive.nationalarchives.gov.uk/20130105045549/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4115784.pdf)

https://webarchive.nationalarchives.gov.uk/20130105045549/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4115784.pdf

[Darzi, Professor the Lord. \(2008\). High Quality Care For All: NHS Next Stage Review Final Report. London: Department of Health.](#)

[First Class Service: Quality in the NHS:1998](#)

[HSC 2003/011 - The interventional procedures programme: working with the National Institute for Clinical Excellence to promote safe clinical innovation](#)

Legal Context of NICE guidance. (2004) www.nice.org.uk
National Quality Board: NICE Quality Standards. (2010)

[NICE - what we do](#)

[Practical steps to improving the quality of care and services using NICE guidance](#)
NICE 2018


[Principles for putting evidence-based guidance into practice](#) NICE 2018

[The Health Foundation. \(2009\) Rising to the challenge: Using evidence about what works to improve quality and save money. London: The Health Foundation.](#)


14.0 Associated documentation

Clinical Audit policy.


Appendix 1: Financial decisions in relation to cost implications.



Appendix 2: NICE Guidance, Relevance, Compliance, Dissemination & Clinical Audits



Appendix 3: Exceptions, assurance and reporting to Divisional Clinical Audit & Effectiveness Groups, Clinical Effectiveness Group, Quality Assurance Committee and Commissioners



Appendix 4

The NHS Constitution

The NHS will provide a universal service for all based on clinical need, not ability to pay. The NHS will provide a comprehensive range of services

Shape its services around the needs and preferences of individual patients, their families and their carers	✓
Respond to different needs of different sectors of the population	✓
Work continuously to improve quality services and to minimise errors	✓
Support and value its staff	✓
Work together with others to ensure a seamless service for patients	✓
Help keep people healthy and work to reduce health inequalities	✓
Respect the confidentiality of individual patients and provide open access to information about services, treatment and performance	✓

Appendix 5 - Stakeholders and Consultation

Key individuals involved in developing the document

Designation
Head of Quality & Professional Practice
Director of Corporate Affairs
Associate Director for Quality Improvement
Clinical Audit Assistant
Clinical Audit Officer
NICE & Effectiveness Officer

Circulated to the following individuals for comment

Designation
Medical Director
Head of Pharmacy
Divisional Clinical Governance lead for Adult Mental Health and Learning Disability
Divisional Clinical Governance Lead for Adults Community Health Services
Head of Nursing, CHS
FYPC Clinical Governance and Quality Lead
Head of Research and Development
Clinical Effectiveness Lead
Quality and Data Analyst
Project Officer, Clinical Practice
Clinical Audit Officer
NICE & Effectiveness Officer
Clinical Director, Adult Mental Health Services
Clinical Director, Learning Disability Services
Clinical Director, Families, Young People and Children's services
Clinical Director, Community Health Services
Pharmacy Services Manager/Clinical Quality and Effectiveness – Trust Lead

Due Regard Screening Template

Section 1			
Name of activity/proposal		The policy outlines the system and processes for the dissemination, implementation and monitoring of NICE and other good practice guidance throughout LPT. National “best practice” guidance enables staff to make evidence based decisions about treatment and healthcare.	
Date Screening commenced		1 September 2020	
Directorate / Service carrying out the assessment		Improvement Knowledge Hub core team	
Name and role of person undertaking this Due Regard (Equality Analysis)		Lyn Williams, Associate Director for Quality Improvement	
Give an overview of the aims, objectives and purpose of the proposal:			
AIMS: To establish a policy and procedure for NICE and other good practice guidance.			
OBJECTIVES: To disseminate, implement and monitor NICE and other good practice.			
Section 2			
Protected Characteristic	If the proposal/s have a positive or negative impact please give brief details		
Age	No		
Disability	No		
Gender reassignment	No		
Marriage & Civil Partnership	No		
Pregnancy & Maternity	No		
Race	No		
Religion and Belief	No		
Sex	No		
Sexual Orientation	No		
Other equality groups?	No		
Section 3			
Does this activity propose major changes in terms of scale or significance for LPT? For example, is there a clear indication that, although the proposal is minor it is likely to have a major affect for people from an equality group/s? Please <u>tick</u> appropriate box below.			
Yes		No ✓	
High risk: Complete a full EIA starting click here to proceed to Part B		Low risk: Go to Section 4.	✓
Section 4			
If this proposal is low risk please give evidence or justification for how you reached this decision:			
The policy outlines the system and processes for the dissemination, implementation and monitoring of NICE and other good practice guidance throughout LPT. National “best practice” guidance enables staff to make evidence based decisions about treatment and healthcare.			
Signed by reviewer/assessor	Lyn Williams	Date	23 September 2020
<i>Sign off that this proposal is low risk and does not require a full Equality Analysis</i>			
Head of Service Signed	Lyn Williams on behalf of Sateesh Gangadharan chair of CANQI committee	Date	13 November 2020

PRIVACY IMPACT ASSESSMENT SCREENING

<p>Privacy impact assessment (PIAs) are a tool which can help organisations identify the most effective way to comply with their data protection obligations and meet individual's expectations of privacy. The first step in the PIA process is identifying the need for an assessment.</p> <p>The following screening questions will help decide whether a PIA is necessary. Answering 'yes' to any of these questions is an indication that a PIA would be a useful exercise and requires senior management support, at this stage the Head of Data Privacy must be involved.</p>			
Name of Document:		Dissemination, implementation and monitoring of National Institute for Health and Care Excellence (NICE) guidance, and other Nationally Agreed Best Practice	
Completed by:		Lyn Williams	
Job title:		Associate Director for Quality Improvement	Date 23 September 2020
			Yes/No
1. Will the process described in the document involve the collection of new information about individuals? This is information in excess of what is required to carry out the process described within the document.			No
2. Will the process described in the document compel individuals to provide information about themselves? This is information in excess of what is required to carry out the process described within the document.			No
3. Will information about individuals be disclosed to organisations or people who have not previously had routine access to the information as part of the process described in this document?			No
4. Are you using information about individuals for a purpose it is not currently used for, or in a way it is not currently used?			No
5. Does the process outlined in this document involve the use of new technology which might be perceived as being privacy intrusive? For example, the use of biometrics.			No
6. Will the process outlined in this document result in decisions being made or action taken against individuals in ways which can have a significant impact on them?			No
7. As part of the process outlined in this document, is the information about individuals of a kind particularly likely to raise privacy concerns or expectations? For examples, health records, criminal records or other information that people would consider to be particularly private.			No
8. Will the process require you to contact individuals in ways which they may find intrusive?			No
<p>If the answer to any of these questions is 'Yes' please contact the Head of Data Privacy Tel: 0116 2950997 Mobile: 07825 947786 Lpt-dataprivacy@leicspart.secure.nhs.uk In this case, adoption of a procedural document will not take place until approved by the Head of Data Privacy.</p>			
IG Manager approval name:			
Date of approval:			

Acknowledgement: Princess Alexandra Hospital NHS Trust